Tharimmune, a clinical-stage biotechnology company, reported a net loss of $8,377,018 for the nine months ended September 30, 2024, compared to a net loss of $6,845,317 for the same period in 2023. The company's net cash used in operating activities was $7,868,344 for the nine months ended September 30, 2024, while net cash provided by financing activities amounted to $1,707,229. Tharimmune's cash balance decreased to $4,774,237 at the end of the period from $10,935,352 at the beginning of the period. The company has been actively developing its product pipeline, including entering into a patent license agreement for TH104 and TH103, and a separate agreement for INT-023/TH023. Tharimmune plans to initiate a Phase 2 trial for TH104 and is developing other therapeutic candidates targeting immuno-oncology targets such as HER2, HER3, and PD-1. The company...Show More

Tharimmune, a clinical-stage biotechnology company, reported a net loss of $8,377,018 for the nine months ended September 30, 2024, compared to a net loss of $6,845,317 for the same period in 2023. The company's net cash used in operating activities was $7,868,344 for the nine months ended September 30, 2024, while net cash provided by financing activities amounted to $1,707,229. Tharimmune's cash balance decreased to $4,774,237 at the end of the period from $10,935,352 at the beginning of the period. The company has been actively developing its product pipeline, including entering into a patent license agreement for TH104 and TH103, and a separate agreement for INT-023/TH023. Tharimmune plans to initiate a Phase 2 trial for TH104 and is developing other therapeutic candidates targeting immuno-oncology targets such as HER2, HER3, and PD-1. The company anticipates IND-enabling studies for TH3215, TH0059, and TH1940 in the coming years. Tharimmune also entered into a nonbinding letter of intent to acquire Intract Pharma Limited, which would enhance its oral biologics capabilities. The company's future plans include advancing its clinical and preclinical candidates, seeking strategic collaborations, and potentially engaging in M&A activities to maximize pipeline value.